OMCLOmnicell, Inc.

Healthcare

$37.79+25% 1Y

$37.79

$29.5752 weeks$51.39

Is the price fair?

Good

Undemanding: modest expectations priced in and cheap against its own history.

2 good, 1 neutral

What the price assumes~−1% a year

Priced for a decline (~−1% a year). The price bakes in little to no growth.

Vs its own P/E rangecheaper than 90% of its own historyderived

Cheap vs its own history: P/E 45.0 vs a 80.9 median over 30 quarters (−44% vs median).

Vs sector (EV/EBIT)26.4×

Sector median 25.1× across 135 covered peers. EV/EBIT counts debt as part of the price, so a cash-rich and a borrowed company can be compared on the same footing.

Unless marked, from derived, as of Jun 30, 2026.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

P/E (valuation)behind 85% of the market

FCF yieldbetter than 79% of the market

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

What OMCL's price assumes

Omnicell, Inc. trades at 45.0× earnings against 46.9× for the median Health Information Services name, cheaper than its own group.

45.0

Trailing P/E · Health Information Services median 46.9 · cheaper than the typical name in its group

Price / sales: 1.38
Price / sales · today's price, trailing year to Jun 30, 2026
Free cash flow yield: 8.3%
Free cash flow yield · Health Information Services median 4.5%
Growth the price implies: −1.1%
Growth the price implies · The price pays for −1.1% free cash flow growth a year for a decade; the business has delivered +0.43% a year over the last three.

Details›

Price / booktoday's price, trailing year to Jun 30, 2026: 1.33
EV / EBITtoday's price, trailing year to Jun 30, 2026: 26.4
EV / salestoday's price, trailing year to Jun 30, 2026: 1.23
Healthcare median P/E503 names: 27.9
Health Information Services median P/E24 names: 46.9
Free cash flow, trailing twelve months: $143M
Market capitalisation45.6 million shares, counted Jul 29, 2026: $1.72B
3-year revenue growth: +0.31%
3-year free cash flow growth: +0.43%

What the market has paid for these earnings: 30 quarters of its own multiple × $0.84 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$50.10
Its own P/E history, median	$67.96
Its own P/E history, upper quartile	$89.72
52-week range	$29.57 – $51.39
Today	$37.79

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.